Immune response to polymorphic malaria antigens and protection against severe malaria in Kenyan children. (360G-Wellcome-073591_Z_03_Z)
Malaria ranks among the top three killers among communicable diseases in tropical developing countries, and mortality rates are increasing, particularly in young children. Older children and adults in endemic years acquire a non-sterilising immunity to malaria such that they remain susceptible to infection but rarely suffer severe disease. Remarkably little is known on how immunity to malaria is acquired. Human, animal model and in vitro studies highlight the importance of antibodies to the erythrocytic stages of the parasite. Likely antibody targets are merozoite proteins and parasite infected erythrocyte surface antigens (PIESA). However, field studies have not consistently related the presence and/or quantity of antibodies to candidate malaria antigens to protection from clinical disease. The evidence suggests that two key issues need to be addressed; better definition of immune status, and parasite polymorphism. Defining immunity to malaria presents an immediate challenge as children are commonly asymptomatically parasitized (apparently immune) and at the same time susceptible to severe life threatening malaria (clearly non-immune). It is thus difficult to identify potentially protective antibody responses when the protected individuals cannot be clearly distinguished from those that are susceptible. The role of parasite polymorphism was evident from early studies showing that immunity to malaria was 'strain specific'. Recently, strong evidence from molecular population genetic analyses supports the hypothesis that immune selection maintains particular parasite antigen polymorphisms. Despite the evidence that polymorphic responses are centrally important, few studies have investigated allele specific antibody responses to candidate antigens. There is particularly strong evidence (from genetic, biological and epidemiological studies) that three polymorphic antigens are important in naturally acquired immunity. These are MSP1 - Block 2, MSP2 and Apical Membrane Antigen (AMA1). This study will prospectively examine the potential protective role of allele specific antibody responses to MSP1, Block 2, MSP2 and AMA1 antigens in children whose immune status in unambiguously defined with severe malaria as the outcome.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Region | International |
| Award Date | 2004-02-05T00:00:00+00:00 |
| Sponsor(s) | Prof Kevin Marsh |
| Internal ID | 073591/Z/03/Z |
| Planned Dates: End Date | 2008-03-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2004-04-01T00:00:00+00:00 |
| Amount Awarded | 80295 |
| Financial Year | 2003/04 |
| Lead Applicant | Prof Faith H A Osier |
| Grant Programme: Title | Training F'ships - Trop/Dev Countries |
| Applicant Surname | Osier |
| Approval Committee | Tropical Interest Group |
| Recipient Org: Country | Kenya |
| Recipient Org: City | Nairobi |
| Has the grant transferred? | No |
| Research conducted at multiple locations? | Yes |
| Total amount including partnership funding | 80295 |